Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Schwab US Large Cap Growth ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Schwab US Large Cap Growth ETF trades at $35.64 (market cap $65.41B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 22.9× Dyne Therapeutics Inc. Common Stock's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Schwab US Large Cap Growth ETF for 52 Days on average.
| DYN | SCHG | |
|---|---|---|
Market Cap | $2.86B | $65.41B |
Volume | 3,341,579 | 6,607,358 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $36.93 |
52-Week Low | $14.60 | $28.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SCHG trades at $36.59 with no daily change, showing stability amid a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent 20% position reduction by Corient Private Wealth. Recent news highlights SCHG's competitive positioning among large-cap growth ETFs with its 0.03% expense ratio and concentration in megacap technology stocks.
The outlook remains positive given SCHG's historical outperformance versus the S&P 500, though concentration risk in top holdings and potential valuation concerns warrant monitoring. Growth investors may benefit from the ETF's low-cost exposure to leading US companies, but should be aware of narrowing performance gaps with broader market alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
